{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:26:34Z","timestamp":1794479194238,"version":"4.9.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014571","name":"Siteman Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.surg.2026.110264","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:28:51Z","timestamp":1776814131000},"page":"110264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Characterization of pathologic complete response to neoadjuvant chemotherapy among breast cancer patients in the National Cancer Database"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3736-9971","authenticated-orcid":false,"given":"Omolade O.","family":"Sogade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin C.","family":"Bowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Margenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2026.110264_bib1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/cancers16020376","article-title":"The impact of different patterns of residual disease on long-term oncological outcomes in breast cancer patients treated with neo-adjuvant chemotherapy","volume":"16","author":"Tinterri","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.surg.2026.110264_bib2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","article-title":"The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB)","volume":"268","author":"Fayanju","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2026.110264_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ijrobp.2019.10.039","article-title":"Nodal response to neoadjuvant chemotherapy predicts receipt of radiation therapy after breast cancer diagnosis","volume":"106","author":"Fayanju","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.surg.2026.110264_bib4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110264_bib5","first-page":"1","article-title":"The neoadjuvant approach to treatment of breast cancer: multidisciplinary management to improve outcomes","volume":"1","author":"Baskin","year":"2024","journal-title":"Surg Oncol Insight"},{"key":"10.1016\/j.surg.2026.110264_bib6","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1245\/s10434-020-09480-9","article-title":"The Landmark series: neoadjuvant chemotherapy for triple-negative and HER2-positive breast cancer","volume":"28","author":"Leon-Ferre","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2026.110264_bib7","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.annonc.2025.09.007","article-title":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer","volume":"36","author":"Burstein","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.surg.2026.110264_bib8","article-title":"FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer","year":"2021","journal-title":"Food Drug Adm"},{"key":"10.1016\/j.surg.2026.110264_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.breast.2021.06.005","article-title":"Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer \u2013 a retrospective cohort study","volume":"59","author":"Davey","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.surg.2026.110264_bib10","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.3390\/cancers15123068","article-title":"Pre- and post-neoadjuvant clinicopathological parameters can help in the prognosis and the prediction of response in HER2+ and triple negative breast cancer","volume":"15","author":"Pons","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.surg.2026.110264_bib11","article-title":"Impact of race and health insurance status on response to neoadjuvant chemotherapy for breast cancer patients","volume":"13","author":"Ho","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.surg.2026.110264_bib12","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/1097-0142(20001201)89:11<2202::AID-CNCR8>3.0.CO;2-L","article-title":"Effects of health insurance and race on breast carcinoma treatments and outcomes","volume":"89","author":"Roetzheim","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2026.110264_bib13","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1001\/archinte.163.18.2135","article-title":"Cancer survival in Kentucky and health insurance coverage","volume":"163","author":"McDavid","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.surg.2026.110264_bib14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/jnci\/94.7.490","article-title":"Race, socioeconomic status, and breast cancer treatment and survival","volume":"94","author":"Bradley","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.surg.2026.110264_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1524-4741.2007.00542.x","article-title":"Treatment variation by insurance status for breast cancer patients","volume":"14","author":"Coburn","year":"2008","journal-title":"Breast J"},{"key":"10.1016\/j.surg.2026.110264_bib16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cam4.84","article-title":"Cancer survival disparities by health insurance status","volume":"2","author":"Niu","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.surg.2026.110264_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJM199307293290507","article-title":"The relation between health insurance coverage and clinical outcomes among women with breast cancer","volume":"329","author":"Ayanian","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surg.2026.110264_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/tbj.13250","article-title":"Association between socioeconomic factors and outcomes in breast cancer","volume":"25","author":"Riba","year":"2019","journal-title":"Breast J"},{"key":"10.1016\/j.surg.2026.110264_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.surg.2018.03.011","article-title":"Race is associated with completion of neoadjuvant chemotherapy for breast cancer","volume":"164","author":"Knisely","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2026.110264_bib20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10549-015-3350-2","article-title":"Race, response to chemotherapy, and outcome within clinical breast cancer subtypes","volume":"150","author":"Tichy","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2026.110264_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2017.73.7932","article-title":"Factors that contributed to Black-White disparities in survival among nonelderly women with breast cancer between 2004 and 2013","volume":"36","author":"Jemal","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.surg.2026.110264_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-020-05599-1","article-title":"Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2\/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB)","volume":"181","author":"Greenwell","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.surg.2026.110264_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251342874","article-title":"Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in non-metastatic HER2-negative breast cancer: a US National Cancer Database analysis","volume":"17","author":"Quiroga","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.surg.2026.110264_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222358","article-title":"Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: a report from the National Cancer Database","volume":"14","author":"Bagegni","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.surg.2026.110264_bib25","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jss.2018.08.011","article-title":"Characterizing response to neoadjuvant chemotherapy in invasive lobular breast carcinoma","volume":"233","author":"Riba","year":"2019","journal-title":"J Surg Res"},{"key":"10.1016\/j.surg.2026.110264_bib26","article-title":"Predictors of nodal pathologic complete response after neoadjuvant chemotherapy in breast cancer","author":"An","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2026.110264_bib27","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606026001893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606026001893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:34:00Z","timestamp":1794476040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606026001893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"alternative-id":["S0039606026001893"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2026.110264","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of pathologic complete response to neoadjuvant chemotherapy among breast cancer patients in the National Cancer Database","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2026.110264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110264"}}